Conservative Balance SheetMinimal leverage and a large equity base provide durable financial resilience. Low debt reduces insolvency risk and preserves capacity to support portfolio companies or fund opportunities through equity or asset sales, improving long-term flexibility during biotech cycles.

Specialized Life-science Investment FocusA clear sector focus on medtech, biotech and pharma creates enduring competitive advantages: domain expertise, targeted deal flow, and value‑add capabilities for portfolio companies. Specialization supports repeatable sourcing and active support over multiple investment cycles.

Revenue Rebound With Strong Gross MarginA sharp revenue recovery and high gross margin indicate the firm can generate operating income from its activities when conditions align. This underlying earning capacity, even if variable, strengthens the base from which the company can fund portfolio support and sustain operations over time.

Bears Say

Large Net Loss And Earnings VolatilityA very large 2025 net loss and prior swings demonstrate structural earnings unpredictability. Such volatility erodes retained capital, complicates strategic planning and makes recurring shareholder returns and reinvestment decisions dependent on timing of exits rather than steady operations.

Uneven Cash Generation And Zero FCFZero free cash flow in the latest year and volatile operating cash flows reduce financial flexibility to support portfolio companies or seize opportunities without realizing assets. Persistent cash unpredictability increases execution risk across investment cycles.

Inconsistent Returns To ShareholdersWide swings in shareholder returns highlight dependence on timing and success of exits. This structural reliance on realized investment events makes dividend or distribution predictability low and complicates long-term income expectations for investors.

LINC FAQ

What was Linc AB’s price range in the past 12 months?

Linc AB lowest stock price was kr58.90 and its highest was kr83.60 in the past 12 months.

What is Linc AB’s market cap?

Linc AB’s market cap is kr4.12B.

When is Linc AB’s upcoming earnings report date?

Linc AB’s upcoming earnings report date is Apr 28, 2026 which is in 46 days.

How were Linc AB’s earnings last quarter?

Linc AB released its earnings results on Jan 22, 2026. The company reported -kr1.868 earnings per share for the quarter, missing the consensus estimate of N/A by -kr1.868.

Is Linc AB overvalued?

According to Wall Street analysts Linc AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Linc AB pay dividends?

Linc AB does not currently pay dividends.

What is Linc AB’s EPS estimate?

Linc AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Linc AB have?

Linc AB has 57,910,446 shares outstanding.

What happened to Linc AB’s price movement after its last earnings report?

Linc AB reported an EPS of -kr1.868 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.613%.

Which hedge fund is a major shareholder of Linc AB?

Currently, no hedge funds are holding shares in SE:LINC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Linc AB

Linc AB is a private equity and venture capital firm, specializing in early, mid and late venture investments in pharmaceutical, life-science and med-tech companies, respectively. The firm prefers to invest in Nordic companies. It usually invests from SEK 25 million to SEK 250 million, the first investment often being a relatively small one and the follow-up investments comprising the larger part of the investment. Linc AB is based in Stockholm, Sweden.private eequity and venture capital firm, specializing in early, mid and late venture investments in pharmaceutical, life-science and med-tech companies, respectively. The firm prefers to invest in Nordic companies. It usually invests from SEK 25 million to SEK 250 million, the first investment often being a relatively small one and the follow-up investments comprising the larger part of the investment. Linc AB is based in Stockholm, Sweden.